Related Experiment Video
Updated: Sep 30, 2026

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
Published on: December 27, 2013
Botulinum toxin in ophthalmology
Abstract:
Alan B. Scott selected, researched and developed Type A Botulinum toxin for clinical use in ophthalmology. This unique drug has proved invaluable for treatment of a number of conditions which are difficult to treat in ophthalmology and in a variety of other disciplines. The indications, methods and problems of its use are described and the results of treatment of 133 patients are discussed. Up to December 1986 over 13,000 patients have been treated in a multicentre international trial without significant complications.
Related Concept Videos
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses
Ophthalmic Drug Delivery Systems
Botulism

